Glaukos (GKOS) Sets a Clear North Star: Q1 2026 Revenue Momentum Raises the Stakes for EPS and Guidance

Overview: A Quarter That Feels like Momentum, Not Noise

Glaukos delivered a record-setting start to 2026, with first-quarter net sales of $150.6 million, marking a 41% increase from the year-ago period on a reported basis and 39% on a constant-currency basis. The glaucoma franchise drove this strength, with U.S. glaucoma net sales rising 58% to $93.5 million, and total glaucoma net sales reaching $129.3 million, up 47% year over year. The company framed the results as evidence of global execution across its commercial and development priorities, an encouraging signal for the revenue forecast attached to the year.

Gross margin stood at roughly 78%, with non-GAAP gross margin around 84% for the quarter. The contrast between high gross profitability and the lack of a disclosed EPS figure in the release invites readers to think about how operating costs and any potential one-time items could shape reported earnings, even as revenue momentum raises the bar for profitability metrics investors care about.

Guidance and What It Signals for EPS and Revenue Forecast

The company raised its 2026 net sales guidance to a range of $620 million to $635 million, up from $600 million to $620 million previously. This move suggests management anticipates revenue growth to outpace earlier estimates, a positive sign for the EPS narrative if the stronger top line translates into higher margins and controlled costs. In practice, investors will be listening not only for a revenue forecast, but for how the company expects operating leverage to flow through to earnings per share (EPS).

Analysts’ EPS consensus and expectations for an earnings surprise depend on more than just top-line gains. With Gross margin in the high-70s and a non-GAAP margin in the mid-80s, the balance of gross profitability, SG&A discipline, and any R&D investments will shape the direction of reported EPS. The absence of explicit EPS data in this excerpt means the market will scrutinize subsequent disclosures or earnings calls for clarity on the EPS trajectory and the potential for an earnings surprise, either positive or negative, relative to consensus forecasts.

Drivers of Growth: iDose TR, Epioxa, and the Dropless Narrative

The release underscores two transformational growth drivers in the pipeline: iDose TR and Epioxa. These platforms, presented as core to Glaukos’s growth strategy, align with an industry-wide push toward longer-lasting, dropless therapies for eye conditions. If the near-term momentum in net sales persists, the question for investors becomes how quickly these products scale internationally, how formulary access evolves, and whether pricing, reimbursement, or competition could broaden or constrain the revenue trajectory.

From a sector perspective, GKOS’s emphasis on expanding its pipeline and maintaining robust gross margins highlights a broader trend among ophthalmology players: profitability increasingly hinges on a combination of high-margin product streams, global reach, and the ability to translate surgical and pharmacologic innovations into sustainable, repeatable revenue.

What This Could Mean for GKOS Peers and the Sector

For Glaukos’s peers, the quarter reinforces the value of diversified product suites within ophthalmology. Companies pursuing dropless or long-acting therapies may see GKOS’s performance as a benchmark for how to blend product launches with margin discipline. The market will likely reassess whether other players can replicate the mix of strong top-line growth and margin resilience that GKOS hints at—an interplay that matters for sector-wide EPS expectations and relative valuation.

Analysts will watch for how currency dynamics, international expansion, and payer landscape impact the EPS consensus across the sector. A couple of questions loom: can GKOS sustain its elevated gross margins while continuing to invest in the pipeline, and will the revenue forecast translate into a steady EPS path that satisfies both the bulls and the skeptics?

Risks and Areas to Watch

• Margin pressure from mix shift or rising operating costs could dampen the EPS trajectory even as revenue grows.
• Dependency on the success and reimbursement of iDose TR and Epioxa—production scale, supply chains, and payer adoption are critical variables.
• Geographic mix and foreign exchange exposures could influence reported results and the translation of revenue growth into earnings.
• Competitive dynamics in glaucoma and corneal disorders—new entrants or alternative therapies could alter the long-run revenue mix.

Takeaway: A Quarter That Aligns Revenue Momentum with a Testy EPS Path

In a world where investors increasingly prize visible revenue acceleration paired with credible margin expansion, Glaukos’s Q1 2026 results place the company on a path that could translate into a favorable EPS outcome—if the cost structure stays disciplined and the pipeline milestones land as expected. The elevated revenue forecast provides a bullish hook, but the next steps—actual EPS delivery, margin trajectory, and the pace of product adoption—will determine whether GKOS can convert momentum into durable profitability.

For readers tracking earnings surprises and EPS consensus, GKOS offers a microcosm of how top-line strength interacts with margins to shape the bottom line. The stock market’s immediate reaction will hinge on whether this quarter’s momentum proves persistent and whether the company can maintain or improve its margin profile as it scales its dropless technologies across geographies.

Bottom line

Glaukos’s first quarter of 2026 demonstrates solid revenue momentum, a favorable margin backdrop, and a raised revenue forecast that could set the stage for a constructive EPS narrative—provided the company can translate top-line growth into per-share profitability. GKOS remains a compelling case study in how specialty medical technology companies balance aggressive product development with the need for sustainable earnings growth, and it will be interesting to see how the sector responds as more detail surfaces in forthcoming filings and earnings calls.